CJC-1295 + Ipamorelin Blend
$125.00
10 mg / vial (5 mg + 5 mg)
Third-Party Tested | U.S.–Made | Research-Grade
Out of stock
Guaranteed safe checkout
Description
Description
CJC-1295 no DAC + Ipamorelin Blend • 10 mg / vial (5 mg + 5 mg)
Tier One Biosystems – Third-Party Tested | U.S.–Made | Research-Grade
Biological Activity
This research blend pairs CJC-1295 (no DAC) / Mod GRF(1-29)—a stabilized GHRH analog—with Ipamorelin, a selective ghrelin (GHSR-1a) agonist. Using a GHRH-pathway peptide alongside a ghrelin-pathway secretagogue is widely studied for synergistic GH pulse amplification versus either alone. Human and animal data show ghrelin agonists amplify GHRH-induced GH secretion and increase pulse amplitude.
In Vivo / In Vitro Data
-
Synergy of pathways: Co-administration of ghrelin mimetics with GHRH produces greater GH release than either alone in multiple models (humans, calves; mechanistic rodent work).
-
CJC-1295 family evidence: Long-acting CJC-1295 (DAC) prolonged GH/IGF-1 elevation in healthy adults (background for the GHRH analog class). (Note: DAC ≠ this product; “no DAC” = Mod GRF(1-29).)
-
Selectivity of Ipamorelin: Ipamorelin stimulates GH release via GHSR-1a with minimal ACTH/cortisol effects versus older GHRPs (preclinical/early clinical literature).
Experimental conditions vary by model; follow your lab’s SOPs and primary literature.
Purity & Documentation
-
Purity (HPLC): ≥99%
-
Independently verified for identity, potency, and sterility
-
COA, SDS, HPLC chromatogram, and LC-MS provided for each lot
Molecular Details
Blend Composition: 5 mg CJC-1295 (no DAC) / Mod GRF(1-29) + 5 mg Ipamorelin per vial.
CJC-1295 (no DAC) / Mod GRF(1-29)
| Property | Value |
|---|---|
| Peptide Type | GHRH(1-29) tetrasubstituted analog |
| Sequence (free base) | H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ |
| Chemical Formula (free base) | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Average Molecular Weight | ≈ 3367.95 g/mol |
| Also known as | Modified GRF(1-29), CJC-1295 without DAC |
| Notes | “No DAC” lacks the albumin-binding DAC extension; distinct from CJC-1295-DAC. |
Ipamorelin
| Property | Value |
|---|---|
| Peptide Type | Ghrelin receptor (GHSR-1a) agonist (pentapeptide) |
| Sequence (free base) | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| Chemical Formula (free base) | C₃₈H₄₉N₉O₅ |
| Average Molecular Weight | ≈ 711.9 g/mol |
| CAS No. | 170851-70-4 |
| Notes | Selective GH secretagogue; commonly combined with GHRH analogs in research. |
Physical Properties
| Property | Specification |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Solubility (in vitro) | Soluble in sterile H₂O, 0.9% NaCl, or buffered aqueous media; DMSO compatible (use minimal volumes) |
| Storage (sealed) | −20 °C (≥12 mo) or −80 °C (≥24 mo); protect from light & moisture |
| Handling | After reconstitution; avoid freezing |
Shipping & Handling
Ships at ambient temperature within the U.S. unless otherwise specified. Maintain cold-chain for long-term storage after receipt.
References
-
Synergy—human: Low-dose ghrelin + GHRH markedly amplifies GH vs. either alone. J Clin Endocrinol Metab. 2001. PubMed
-
Synergy—calves: Combined ghrelin + GHRH synergistically stimulated GH release in pre-weaning calves. Domest Anim Endocrinol. 2008. PubMed
-
Mechanism: Ghrelin activates GHRH neurons (mouse), supporting pathway complementarity. PLOS One. 2010. PLOS
-
CJC-1295 background (DAC): Prolonged GH/IGF-1 elevation in adults. JCEM. (human). (Background for the class; DAC ≠ this product.) Wikipedia
-
Spec data—Mod GRF(1-29): Sequence & C₁₅₂H₂₅₂N₄₄O₄₂, MW ≈ 3367.95 g/mol. Vendor/spec pages.
-
Spec data—Ipamorelin: C₃₈H₄₉N₉O₅, MW ≈ 711.9 g/mol, CAS 170851-70-4. PubChem / vendor spec. PubChem+1
Research Use Only – Not for Human Consumption
Supplied exclusively for laboratory research, analytical testing, and scientific investigation.
Reviews (0)
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.